<DOC>
	<DOCNO>NCT02260648</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy safety study drug know evacetrapib administer combination atorvastatin 12 week Japanese participant primary hypercholesterolemia .</brief_summary>
	<brief_title>A Study Evacetrapib ( LY2484595 ) Combination With Atorvastatin Japanese Participants With Primary Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Must treat atorvastatin 10 mg/day least 30 day prior study initiation . Japanese outpatient diagnose primary hypercholesterolemia LDLC level ( measure direct method ) meet follow criterion . ( Participant category base definition Japan Atherosclerosis Society 2012 guideline . ) Category I : 160 mg/deciliter ( dL ) ≤LDLC Category II : 140 mg/dL≤LDLC Category III : 120 mg/dL≤LDLC Secondary prevention : 100 mg/dL≤LDLC Have triglyceride ( TG ) ≤400 mg/dL . Have HDLC &lt; 100 mg/dL . Participants LDL apheresis plasma apheresis . Participants secondary hypercholesterolemia homozygous familial hypercholesterolemia . Any planned angiography . If angiography plan , participant may screen enrol planned procedure complete . History follow condition &lt; 90 day prior study initiation acute coronary syndrome ( unstable angina , acute myocardial infarction ) symptomatic peripheral arterial disease invasive treatment carotid artery disease ischemic stroke transient ischemic attack ( TIA ) intracranial hemorrhage History abdominal aortic aneurysm . Participants history intolerance/hypersensitivity ezetimibe statin . Have systolic blood pressure ( SBP ) &gt; 160 millimeter mercury ( mm Hg ) diastolic blood pressure ( DBP ) &gt; 100 mm Hg . Have hemoglobin A1c ≥8.4 % ( National Glycohemoglobin Standardization Program ) . During study period , participant plan use , likely require , unwilling unable stop adequate washout prescription , counter ( OTC ) medication , supplement health food intent treat serum lipid ( LDLC , HDLC , TG ) include limited class drug : statin ( except atorvastatin 10 mg ) , ezetimibe , bile acid sequestrant , eicosapentaenoic acid ( EPA ) docosahexaenoic acid ( DHA ) . Participants take probucol , fibrate nicotinic agent within 8 week study initiation exclude study . Have expose cholesteryl ester transfer protein ( CETP ) inhibitor ( example , anacetrapib dalcetrapib ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>